(19)
(11) EP 1 725 536 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.04.2009 Bulletin 2009/17

(45) Mention of the grant of the patent:
15.10.2008 Bulletin 2008/42

(21) Application number: 05716710.8

(22) Date of filing: 16.02.2005
(51) International Patent Classification (IPC): 
C07D 233/28(2006.01)
(86) International application number:
PCT/EP2005/050680
(87) International publication number:
WO 2005/080345 (01.09.2005 Gazette 2005/35)

(54)

IMIDAZOLINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY

IMIDAZOLINDERIVATE MIT CB1-ANTAGONISTISCHER WIRKUNG

DERIVES DE L'IMIDAZOLINE PRESENTANT UNE ACTIVITE ANTAGONISTE CB1

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
HR LV

(30) Priority: 19.02.2004 EP 04100656
19.02.2004 US 545484 P

(43) Date of publication of application:
29.11.2006 Bulletin 2006/48

(73) Proprietor: Solvay Pharmaceuticals B.V.
1381 CP Weesp (NL)

(72) Inventors:
  • LANGE, Josephus H. M., p/o IPSI DEPARTMENT
    NL-1381 CP Weesp (NL)
  • KRUSE, Cornelis G., p/o IPSI DEPARTMENT
    NL-1381 CP Weesp (NL)
  • VAN STUIVENBERG, Herman H., p/o IPSI DEPARTMENT
    NL-1381 CP Weesp (NL)

(74) Representative: Verhage, Marinus et al
Octrooibureau Zoan B.V. P.O. Box 140
1380 AC Weesp
1380 AC Weesp (NL)


(56) References cited: : 
WO-A-03/026647
WO-A-03/078413
 WO-A-03/027076
WO-A-03/101969
   
  • LANGE J H M ET AL: "SYNTHESIS, BIOLOGICAL PROPERTIES, AND MOLECULAR MODELING INVESTIGATIONS OF NOVEL 3,4-DIARYLPYRAZOLINES AS POTENT AND SELECTIVE CB1 CANNABINOID RECEPTOR ANTAGONISTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 3, 30 December 2003 (2003-12-30), pages 627-643, XP001188902 ISSN: 0022-2623
  • KHANNA I K ET AL: "SELECTIVE CYCLOOXYGENASE-2 INHIBITORS: HETEROARYL MODIFIED 1,2-DIARYLIMIDAZOLES ARE POTENT, ORALLY ACTIVE ANTIINFLAMMATORY AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 16, 2000, pages 3168-3185, XP001026112 ISSN: 0022-2623
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).